SLC17A7 and tauopathy: Moreover, reducing VGlut1 levels and glutamate release rescued cognitive deficits in tauP301L pos mice (Hunsberger et al., 2015), suggesting the increased VGlut1 and/or glutamate release may represent potential therapeutic targets for the treatment of early-stage tauopathies.